Sanders, C. v. The Children's Hosp. ( 2022 )


Menu:
  • J-A11003-22
    
    2022 PA Super 199
    CHRISTIANA SANDERS AND BRYAN            :   IN THE SUPERIOR COURT OF
    SANDERS, AS CO-ADMINISTRATORS           :        PENNSYLVANIA
    OF THE ESTATE OF M.S., AND              :
    CHRISTIANA SANDERS AND BRYAN            :
    SANDERS, IN THEIR OWN RIGHT             :
    :
    :
    v.                         :
    :
    :
    THE CHILDREN’S HOSPITAL OF              :
    PHILADELPHIA                            :
    :   No. 646 EDA 2021
    Appellant             :
    Appeal from the Order Entered March 12, 2021
    In the Court of Common Pleas of Philadelphia County Civil Division at
    No(s): No. 171204286
    SHEILA LIMPREVIL, AS CO-                :   IN THE SUPERIOR COURT OF
    ADMINISTRATOR OF THE ESTATE OF          :        PENNSYLVANIA
    L.G.W., AND SHEILA LIMPREVIL, IN        :
    HER OWN RIGHT AND TERRELL               :
    WILLIAMS, AS CO-ADMINISTRATOR           :
    OF THE ESTATE OF L.G.W., AND            :
    TERRELL WILLIAMS, IN HIS OWN            :
    RIGHT                                   :
    :
    :
    v.                         :
    :
    :
    THE CHILDREN’S HOSPITAL OF              :
    PHILADELPHIA                            :
    :   No. 648 EDA 2021
    Appellant             :
    Appeal from the Order Entered March 12, 2021
    In the Court of Common Pleas of Philadelphia County Civil Division at
    No(s): No. 180802309
    J-A11003-22
    COURTNEY GILL, AS               :            IN THE SUPERIOR COURT OF
    ADMINISTRATRIX OF THE ESTATE OF :                 PENNSYLVANIA
    T.C.G., AND COURTNEY GILL AND   :
    TERRENCE GILL, IN THEIR OWN     :
    RIGHT                           :
    :
    :
    v.                   :
    :
    :
    THE CHILDREN’S HOSPITAL OF      :
    PHILADELPHIA                    :
    :            No. 659 EDA 2021
    Appellant       :
    Appeal from the Order Entered March 12, 2021
    In the Court of Common Pleas of Philadelphia County Civil Division at
    No(s): No. 180900385
    BEFORE: BOWES, J., STABILE, J., and McLAUGHLIN, J.
    OPINION BY BOWES, J.:                             FILED NOVEMBER 22, 2022
    Before us are three consolidated interlocutory appeals from orders
    which, inter alia, overruled the privilege objections of Children’s Hospital of
    Philadelphia (“CHOP”) to the discovery requests of the appellees (collectively
    “Plaintiffs”), who are the parents and estate administrators of three infants
    who died after contracting an adenovirus in CHOP’s neonatal intensive care
    unit (“NICU”).1 We affirm in part, reverse in part, and remand for further
    proceedings consistent with this opinion.
    ____________________________________________
    1   This Court has jurisdiction over these appeals because they are from
    collateral orders that are immediately appealable pursuant to Pa.R.A.P. 313.
    See, e.g., Farrell v. Regola, 
    150 A.3d 87
    , 95 (Pa.Super. 2016) (“When a
    party is ordered to produce materials purportedly subject to a privilege, we
    have jurisdiction under Pa.R.A.P. 313.” (cleaned up)).
    -2-
    J-A11003-22
    I.     Facts and Procedural History
    Twenty-three infants, including Plaintiffs’ decedents, contracted an
    adenovirus in CHOP’s NICU in the late summer of 2016. CHOP’s Infection
    Prevention & Control (“IP&C”) Department became aware of the cluster of
    adenovirus cases on August 22, 2016. It therefore began an investigation
    pursuant to CHOP’s IP&C Plan “to find the cause and stop the outbreak,” led
    by Dr. Julia Sammons, CHOP’s attending infectious disease physician, chair of
    the IP&C Committee, and a member of CHOP’s Patient Safety Committee.
    Sammons Deposition, 10/6/20, at 40.              Dr. Sammons reported to Dr. Jan
    Boswinkel, CHOP’s designated Patient Safety Officer pursuant to the Medical
    Care Availability and Reduction of Error (“MCARE”) Act, 40 P.S. §§ 1303.101-
    1303.910.
    The fruits of the investigation were as follows. Dr. Sammons discovered
    that the common event experienced by all infected babies was a retinopathy
    of prematurity (“ROP”) eye examination. See Sammons Deposition, 10/6/20,
    at 32.2    Subsequent testing of the equipment used in the examinations,
    namely a hand-held lens and an indirect ophthalmoscope that never came in
    contact with the patients, revealed the presence of the adenovirus. Id. at 32-
    35. After observing the physicians perform ROP examinations, Dr. Sammons
    ____________________________________________
    2  Dr. Sammons’s deposition appears in the certified record as Exhibit B to
    Plaintiffs’ Reply to CHOP’s Response to Plaintiffs’ Motion to Strike Privilege
    Objections filed on February 4, 2021.
    -3-
    J-A11003-22
    ultimately concluded that the virus was transmitted to each of the patients by
    the doctor touching the contaminated equipment and then touching the
    babies.    Id. at 38-40.      Accordingly, while CHOP had no hand hygiene or
    equipment-specific cleaning policies for ROP examinations prior to the
    outbreak, CHOP instituted both hand hygiene protocols and required bleach
    cleaning of the equipment as a result of the investigation. Id. at 36, 123,
    131.
    In the process of gathering the information to make the above
    discoveries, conclusions, and recommendations, the following meetings
    occurred. Dr. Sammons reported to the Patient Safety Committee on August
    25, 2016, regarding the investigation to date. The Committee requested that
    Dr. Sammons persist with her efforts and continue to provide updates. See
    Sammons Affidavit, 2/19/21, at 2-3.3 Between August 24 and September 6,
    2016, Dr. Sammons periodically held “safety huddles” with members of the
    IP&C Department and with doctors and nurses in the NICU, involving the
    sharing of PowerPoint slides on August 24, 25, 29, 30, and 31, as well as
    September 2, and 6, 2016.           Id. at 4-5.   While these safety huddles were
    “frequently coordinated with the Patient Safety Officer,” many of these
    meetings “were impromptu ad hoc meetings” outside of the established
    ____________________________________________
    3 Dr. Sammons’s affidavit appears in the certified record as Exhibit A to
    CHOP’s Supplemental Brief in Opposition to Plaintiffs’ Motion to Strike Privilege
    Objections filed on February 19, 2021.
    -4-
    J-A11003-22
    Patient Safety Committee meetings for the collection and review of data. Id.
    at 3; Sammons Deposition, 10/6/20, at 216. In addition to the sharing of
    information, the meetings involved the evaluation of the actions of
    professional health care providers, the quality of patient safety measures, and
    recommendations for new or modified patient safety methods. Id. at 3.
    On September 14 and October 12, 2016, Dr. Sammons and other
    members of the IP&C Department reported to the IP&C Committee, utilizing
    PowerPoint slides. These presentations involved the evaluation of IP&C and
    NICU providers, discussions of possible improvements to health care quality,
    and suggestions for new procedures and the monitoring of compliance
    therewith. Id. at 6. A similar presentation, also including PowerPoint slides,
    was given to CHOP’s Patient Safety Committee on September 22, 2016. Id.
    CHOP held several Morbidity and Mortality (“M&M”) conferences related
    to the outbreak. Specifically, on September 26, 2016, Dr. Sammons and other
    doctors, utilizing PowerPoint slides, presented a Patient Safety M&M at
    Dr. Boswinkel’s request as a subcommittee of the Patient Safety Committee.
    Id. at 7-8.   On October 4, 2016, PowerPoint presentations were made in
    furtherance of “peer review and improving the quality of health care” to
    professional health care providers at NICU and Ophthalmology M&M
    conferences “to evaluate the services performed by other professional health
    care providers, conduct practice analysis, and recommend improvements for
    . . . services provided to CHOP patients.” Id. at 8-9. Similar programs, with
    -5-
    J-A11003-22
    slides, were presented at CHOP Ophthalmology Residents and Surgical
    Division Chiefs M&M conferences on October 10 and 11, 2016, respectively,
    as well as at the University of Pennsylvania’s Scheie Eye Institute’s M&M Grand
    Rounds Conference on January 17, 2017. Id. at 9-11.
    In the meantime, CHOP’s Patient Safety Committee directed a formal
    root cause analysis (“RCA”) of the outbreak which resulted in an RCA report.
    That report, which was submitted to the Patient Safety Committee,
    summarized the gathering and evaluation of the information about the
    outbreak and proposed a plan for preventing another one. Id. at 11. The
    RCA report was presented to the Patient Safety Committee at its November
    17, 2016 meeting.
    Believing that the transmission of the virus through ophthalmology
    equipment that does not come into direct contact with the patient was a novel
    finding, Dr. Sammons also published an abstract and article about the
    outbreak. Neither utilized any of the documents created during the course of
    the investigation, but referenced the facts of the outbreak. Additionally, one
    month after the outbreak, Dr. Monte Mills, the chief of CHOP’s Ophthalmology
    Division, and Dr. Albert Maguire, an ophthalmologist who was not part of the
    NICU treating team, exchanged emails concerning Dr. Maguire’s desire to
    discuss the finding of the investigation in a paper. The subject of the email
    was “NICU consult hygiene/infection control.”
    -6-
    J-A11003-22
    In December 2017 and August 2018, Plaintiffs filed survival and
    wrongful    death     actions    against       CHOP    alleging   medical   malpractice.
    Specifically, Plaintiffs contended that CHOP was negligent in failing to follow
    proper procedures for disinfecting the ophthalmology equipment. During the
    course of discovery, Plaintiffs issued discovery requests to which the above-
    identified documents were responsive.                 CHOP compiled a privilege log
    identifying the documents and asserting privilege.                CHOP also produced
    affidavits from Drs. Sammons and Boswinkel asserting that the documents at
    issue were created at the behest of CHOP’s Patient Safety Committee and
    Officer for purposes of complying with its obligations pursuant to the MCARE
    Act and “to conduct peer review.” See, e.g., Boswinkel Affidavit, 2/19/21, at
    6.4
    The trial court conducted an in camera review of the documents and
    entertained written argument from the parties concerning the import and
    consistency of the affidavits and the deposition testimony of Dr. Sammons
    about the context and purposes of her investigation into the outbreak.
    Thereafter, the trial court determined that CHOP failed to establish that certain
    of the documents discussed above were privileged under the Peer Review
    Protection Act (“PRPA”) or MCARE, and ordered their production to Plaintiffs.
    ____________________________________________
    4 Dr. Boswinkel’s affidavit appears in the certified record as Exhibit B to
    CHOP’s Supplemental Brief in Opposition to Plaintiffs’ Motion to Strike Privilege
    Objections filed on February 19, 2021.
    -7-
    J-A11003-22
    This timely appeal followed, and both CHOP and the trial court complied with
    Pa.R.A.P. 1925.
    CHOP presents the following two claims on appeal:
    1.    Whether the trial court erred and abused its discretion
    in concluding that a hospital failed to establish that certain
    documents prepared for peer review and patient safety purposes
    (including the hospital’s Root Cause Analysis, PowerPoint
    presentations, meeting minutes, intranet postings and emails)
    were protected from discovery by the [PRPA] or the [MCARE Act]
    where: (1) the materials were prepared in accordance with the
    statutes’ respective requirements; (ii) the hospital identified the
    bases for each privilege on logs and affidavits; and (iii) the
    hospital protected the documents from the public disclosure?
    2.    Whether the trial court erred and abused its discretion
    in concluding that a defendant hospital waived its right to claim
    protection under the PRPA and MCARE simply by publishing an
    article and an abstract about the subject matter of documents
    where: (1) the article and abstract merely referenced facts from
    the privileged documents but did not disclose the documents
    themselves; (ii) nothing in any statute or common law supports a
    finding of waiver; and (iii) the article and abstract provided
    potentially lifesaving information about a novel medical finding;
    thus, any decision requiring the documents to be disclosed
    violates public policy?
    CHOP’s brief at 4. As CHOP’s two questions present intertwined concepts, we
    address each aspect organically within our discussion rather than as distinct
    issues.
    II.   Applicable Law
    Initially, we note the general legal principles that guide our review. “The
    issue of whether materials are privileged is a question of law.”        Meyer-
    Chatfield Corp. v. Bank Fin. Servs. Grp., 
    143 A.3d 930
    , 937 (Pa.Super.
    2016). Therefore, this Court conducts a de novo, plenary review. 
    Id.
     To the
    -8-
    J-A11003-22
    extent that our review entails statutory interpretation, it also implicates
    questions of law subject to de novo, plenary review.                  See, e.g.,
    Commonwealth v. Chesapeake Energy Corp., 
    247 A.3d 934
    , 942 (Pa.
    2021).   “The object of all interpretation and construction of statutes is to
    ascertain and effectuate the intention of the General Assembly.” 1 Pa.C.S.
    § 1921(a).   “The plain language of the statute is the best indicator of the
    legislature’s intent. To ascertain the plain meaning, we consider the operative
    statutory language in context and give words and phrases their common and
    approved usage.” Chesapeake Energy Corp., supra at 942.
    It is well-settled that evidentiary privileges are disfavored, and that their
    use should be permitted “only to the very limited extent that excluding
    relevant evidence has a public good transcending the normally predominant
    principle of utilizing all rational means for ascertaining the truth.” BouSamra
    v. Excela Health, 
    210 A.3d 967
    , 975 (Pa. 2019) (cleaned up). Regarding
    the respective duties of the parties when a privilege is invoked, we have
    observed that “[t]he party invoking a privilege must initially set forth facts
    showing that the privilege has been properly invoked.” Yocabet v. UPMC
    Presbyterian, 
    119 A.3d 1012
    , 1019 (Pa.Super. 2015) (cleaned up). “Once
    the invoking party has made the appropriate proffer, then the burden shifts
    to the party seeking disclosure to set forth facts showing that disclosure should
    be compelled either because the privilege has been waived or because an
    exception to the privilege applies.” 
    Id.
     (cleaned up).
    -9-
    J-A11003-22
    A.     The PRPA
    Turning to the specific privileges at issue in this appeal, we first examine
    the scope of the peer review privilege codified by the PRPA.5              Having
    determined that, “because of the expertise and level of skill required in the
    practice of medicine, the medical profession itself is in the best position to
    police its own activities,” our legislature enacted the PRPA “to serve the
    legitimate purpose of maintaining high professional standards in the medical
    practice for the protection of patients and the general public[.]” Reginelli v.
    Boggs, 
    181 A.3d 293
    , 300 (Pa. 2018) (cleaned up). The act encourages the
    “the increased use of peer review groups by giving protection to individuals
    and data who report to any review group[.]”            Leadbitter v. Keystone
    Anesthesia Consultants, Ltd., 
    256 A.3d 1164
    , 1169 (Pa. 2021) (cleaned
    up). “These types of protections are viewed as helpful in fostering effective
    peer review because of the perceived reluctance of members of the medical
    community to criticize their peers and take corrective action.” 
    Id.
     In sum,
    “the PRPA is designed to foster candor and frankness in the creation and
    consideration of peer-review data by conferring immunity from liability, as
    well as confidentiality — all with the objectives of improving the quality of
    ____________________________________________
    5 On August 29, 2022, Plaintiffs filed an application for post-submission
    communication suggesting that we consider this Court’s decision in Williams
    v. GEO Grp., Inc., ___ A.3d ___, 
    2022 PA Super 148
    , 
    2022 WL 3640469
     at
    *4 (Pa.Super. Aug. 24, 2022), in connection with the reach of the PRPA’s
    privilege. Since that decision was withdrawn by order of October 19, 2022,
    we deny the application.
    - 10 -
    J-A11003-22
    care, reducing mortality and morbidity, and controlling costs.” Leadbitter,
    supra at 1169.
    The confidentiality provision of the PRPA is as follows:
    The proceedings and records of a review committee shall be held
    in confidence and shall not be subject to discovery or introduction
    into evidence in any civil action against a professional health care
    provider arising out of the matters which are the subject of
    evaluation and review by such committee and no person who was
    in attendance at a meeting of such committee shall be permitted
    or required to testify in any such civil action as to any evidence or
    other matters produced or presented during the proceedings of
    such committee or as to any findings, recommendations,
    evaluations, opinions or other actions of such committee or any
    members thereof:         Provided, however, [t]hat information,
    documents or records otherwise available from original sources
    are not to be construed as immune from discovery or used in any
    such civil action merely because they were presented during
    proceedings of such committee, nor should any person who
    testifies before such committee or who is a member of such
    committee be prevented from testifying as to matters within his
    knowledge, but the said witness cannot be asked about his
    testimony before such a committee or opinions formed by him as
    a result of said committee hearings.
    63 P.S. § 425.4. The definition section of the PRPA includes the following
    terms:
    “Peer review” means the procedure for evaluation by
    professional health care providers of the quality and efficiency of
    services ordered or performed by other professional health care
    providers, including practice analysis, inpatient hospital and
    extended care facility utilization review, medical audit, ambulatory
    care review, claims review, and the compliance of a hospital,
    nursing home or convalescent home or other health care facility
    operated by a professional health care provider with the standards
    set by an association of health care providers and with applicable
    laws, rules and regulations. . . .
    “Professional health care provider” means:
    - 11 -
    J-A11003-22
    (1) individuals or organizations who are approved, licensed or
    otherwise regulated to practice or operate in the health care field
    under the laws of the Commonwealth, including, but not limited
    to, the following individuals or organizations:
    (i) a physician;
    ....
    (viii) a registered or practical nurse;
    ....
    (x) an administrator of a hospital, nursing or convalescent
    home or other health care facility; or
    (xi) a corporation or other organization operating a hospital,
    nursing or convalescent home or other health care facility[.]
    ....
    “Review organization” means any committee engaging in peer
    review, including a hospital utilization review committee, a
    hospital tissue committee, a health insurance review committee,
    a hospital plan corporation review committee, a professional
    health service plan review committee, a dental review committee,
    a physicians’ advisory committee, a veterinary review committee,
    a nursing advisory committee, any committee established
    pursuant to the medical assistance program, and any committee
    established by one or more State or local professional societies,
    to gather and review information relating to the care and
    treatment of patients for the purposes of (i) evaluating and
    improving the quality of health care rendered; (ii) reducing
    morbidity or mortality; or (iii) establishing and enforcing
    guidelines designed to keep within reasonable bounds the cost of
    health care. It shall also mean any hospital board, committee or
    individual reviewing the professional qualifications or activities of
    its medical staff or applicants for admission thereto. It shall also
    mean a committee of an association of professional health care
    providers reviewing the operation of hospitals, nursing homes,
    convalescent homes or other health care facilities.
    63 P.S. § 425.2. The term “review committee” is not defined in the PRPA, but
    has been determined to mean “any committee that undertakes peer review.”
    - 12 -
    J-A11003-22
    Leadbitter, supra at 1176 (cleaned up). The word “proceedings” also is not
    included in the definition section of the PRPA, but has been interpreted to
    include a claim or other document received by a committee member in his
    official capacity that initiates the peer review process.      See Steel v.
    Weisberg, 
    534 A.2d 814
    , 817 (Pa.Super. 1987).
    Where a committee does not exclusively perform peer review functions,
    “only peer-review documents are [subject to the privilege], and not the
    committee’s documents more broadly.” 
    Id.
     at 1178 n.19. The privilege does
    not “protect non-peer review business records, even if those records
    eventually are used by a peer review committee.” Dodson v. DeLeo, 
    872 A.2d 1237
    , 1243 (Pa.Super. 2005). As we explained:
    a hospital cannot create protection for a document simply by
    sending it to the peer review committee. On the other hand,
    documents generated by a peer review committee specifically for
    use in the peer review process are not discoverable simply
    because some of the information contained therein is available
    elsewhere. To hold otherwise would have a chilling effect on the
    peer review process and would clearly run afoul of the purpose of
    the statute.
    
    Id. at 1244
     (cleaned up).
    In other words, the scope of the privilege afforded by the PRPA “is
    limited to documents of a review committee that it utilized when it engaged
    in peer review.” 
    Id.
     (cleaned up). As such, the PRPA offers privilege only to
    materials prepared in furtherance of “(i) evaluating and improving the quality
    of health care rendered; (ii) reducing morbidity or mortality; or (iii)
    - 13 -
    J-A11003-22
    establishing and enforcing guidelines designed to keep within reasonable
    bounds the cost of health care.” 63 P.S. § 425.2.
    B.     The MCARE Act
    The MCARE Act was enacted to further the following policies: “to ensure
    that medical care is available in this Commonwealth through a comprehensive
    and high-quality health care system” and “to reduce and eliminate medical
    errors by identifying problems and implementing solutions that promote
    patient safety.” 40 P.S. § 1303.102(1), (5). The patient safety chapter of the
    MCARE Act, 40 P.S. §§ 1303.301-1303.315, “relates to the reduction of
    medical errors for the purpose of ensuring patient safety.”               40 P.S.
    § 1303.301.
    For example, § 307(b)(3) requires medical facilities to develop and
    implement patient safety plans that, inter alia, establish a system for its health
    care workers to report serious events6 and incidents.7 Section § 309 provides
    that a patient safety officer must “[e]nsure the investigation of all reports of
    ____________________________________________
    6 A serious event is “[a]n event, occurrence or situation involving the clinical
    care of a patient in a medical facility that results in death or compromises
    patient safety and results in an unanticipated injury requiring the delivery of
    additional health care services to the patient. The term does not include an
    incident.” 40 P.S. § 1303.302.
    7  The definition of the term “incident” excludes serious events and states that
    it is “[a]n event, occurrence or situation involving the clinical care of a patient
    in a medical facility which could have injured the patient but did not either
    cause an unanticipated injury or require the delivery of additional health care
    services to the patient.” 40 P.S. § 1303.302.
    - 14 -
    J-A11003-22
    serious events and incidents,” take any action “immediately necessary to
    ensure patient safety as a result of any investigation,” and to report actions
    taken as a result of an investigation to promote patient safety to the patient
    safety committee. 40 P.S. § 1303.309(2)-(4). As for the composition of a
    patient safety committee, the MCARE Act specifies as follows:
    A hospital’s patient safety committee shall be composed of the
    medical facility’s patient safety officer and at least three health
    care workers of the medical facility and two residents of the
    community served by the medical facility who are not agents,
    employees or contractors of the medical facility. No more than
    one member of the patient safety committee shall be a member
    of the medical facility’s board of trustees. The committee shall
    include members of the medical facility’s medical and nursing
    staff. The committee shall meet at least monthly.
    40 P.S. § 1303.310(a)(1).
    Pursuant to § 308, “A health care worker who reasonably believes that
    a serious event or incident has occurred shall report the serious event or
    incident according to the patient safety plan of the medical facility unless the
    health care worker knows that a report has already been made.”           40 P.S.
    § 1303.308(a).
    Subsection 310(b) imposes on a medical facility’s patient safety
    committee the obligations to:
    (1) Receive reports from the patient safety officer pursuant to
    section 309.
    (2) Evaluate investigations and actions of the patient safety officer
    on all reports.
    (3) Review and evaluate the quality of patient safety measures
    utilized by the medical facility.  A review shall include the
    - 15 -
    J-A11003-22
    consideration of reports made under sections 304(a)(5) and (b),
    307(b)(3) and 308(a).
    (4) Make recommendations to eliminate future serious events and
    incidents.
    (5) Report to the administrative officer and governing body of the
    medical facility on a quarterly basis regarding the number of
    serious events and incidents and its recommendations to eliminate
    future serious events and incidents.
    40 P.S. § 1303.310(b).
    Since a patient safety committee organized pursuant to § 310(a)(1) of
    the MCARE Act includes members of the community that are not professional
    health care providers, the patient safety committee cannot constitute a peer
    review committee whose proceedings are protected by the PRPA.               See
    Ungurian v. Beyzman, 
    232 A.3d 786
    , 800 (Pa.Super. 2020) (“Because the
    Patient Safety Committee includes members of the community served by
    Hospital, the Committee is not exclusively comprised of ‘professional
    healthcare providers.’ Accordingly, Hospital failed to satisfy its evidentiary
    burden of proving the applicability of the PRPA privilege to the Patient Safety
    Committee Meeting Minutes.”). Instead, the MCARE Act contains a separate
    confidentiality provision which provides as follows in pertinent part:
    (a) Prepared materials.--Any documents, materials or
    information solely prepared or created for the purpose of
    compliance with section 310(b) or of reporting under section . . .
    307(b)(3), 308(a), 309(4), [or] 310(b)(5) . . . which arise out of
    matters reviewed by the patient safety committee pursuant to
    section 310(b) . . . are confidential and shall not be discoverable
    or admissible as evidence in any civil or administrative action or
    proceeding. Any documents, materials, records or information
    that would otherwise be available from original sources shall not
    - 16 -
    J-A11003-22
    be construed as immune from discovery or use in any civil or
    administrative action or proceeding merely because they were
    presented to the patient safety committee . . . .
    (b) Meetings.--No person who performs responsibilities for or
    participates in meetings of the patient safety committee . . .
    pursuant to section 310(b) shall be allowed to testify as to any
    matters within the knowledge gained by the person’s
    responsibilities or participation on the patient safety committee
    . . . provided, however, the person shall be allowed to testify as
    to any matters within the person’s knowledge which was gained
    outside of the person’s responsibilities or participation on the
    patient safety committee . . . pursuant to section 310(b).
    (c) Applicability.--The confidentiality protections set forth in
    subsections (a) and (b) shall only apply to the documents,
    materials or information prepared or created pursuant to the
    responsibilities of the patient safety committee . . . set forth in
    section 310(b).
    40 P.S. § 1303.311.
    Hence, to be privileged pursuant to the MCARE Act, the materials must:
    (1) be solely prepared for compliance with an enumerated MCARE Act duty,
    (2) arise out of matters reviewed by the patient safety committee in
    accordance with § 310(b), and (3) not be otherwise available from original
    sources. See 40 P.S. § 1303.311(a). See also Venosh v. Henzes, 11 CV
    3058, 
    2013 WL 9593953
     (Lackawanna County C.C.P. July 17, 2013), aff’d,
    
    105 A.3d 788
     (Pa.Super. 2014) (unpublished memorandum) (gleaning from
    the plain language of § 311 the foregoing three requirements for MCARE Act
    confidentiality to apply).
    III. Analysis
    We now proceed to apply the above statutes to each of the documents
    at issue in this appeal seriatim.
    - 17 -
    J-A11003-22
    A.    The Root Cause Analysis Report
    The trial court ruled that the RCA report was not protected because
    “CHOP has failed to meet their burden in proving which specific privilege
    applies supported by sufficient information proving that this report was
    created specifically for the hospital’s event reporting system or peer review
    committee meeting by including such information as who prepared the report
    and when it was prepared.” Trial Court Opinion, 7/19/21, at 8.
    The trial court’s conclusion is belied by the record. CHOP produced the
    affidavit of Dr. Boswinkel, CHOP’s designated Patient Safety Officer pursuant
    to the MCARE Act, who indicated that the report was prepared by a “root cause
    analysis team” at the behest of the Patient Safety Committee. See Boswinkel
    Affidavit, 2/19/21, at 5. The report was marked as confidential and annotated
    with “Peer Review/MCARE Protected” and was submitted to the Patient Safety
    Committee and presented at its November 17, 2016 official meeting. Id. at
    6.   The function of the root cause analysis report was to satisfy “the
    responsibilities of the Patient Safety Committee under MCARE Act Section
    310(b), including evaluating the quality of patient safety measures in place
    and recommending steps to eliminate future series events and incidents,” as
    well as the duty “as the Patient Safety Officer under MCARE Act Section 309(4)
    to report to the Patient Safety Committee regarding actions taken to promote
    patient safety.”   Id.   CHOP also produced Dr. Sammons’s affidavit which
    indicated that she was a member of the root cause analysis team and that the
    - 18 -
    J-A11003-22
    team compiled the report and presented it to the Patient Safety Committee at
    Dr. Boswinkel’s direction to evaluate the existing patient safety measures and
    recommend steps to eliminate future serious events. See Sammons Affidavit,
    2/19/21, at 11.
    Plaintiffs rightly argue in their brief that the root cause analysis report
    was not protected by the PRPA. See Plaintiff’s brief at 30-32. We agree that
    CHOP did not establish that the PRPA privilege attached to the root cause
    analysis. See Ungurian v. Beyzman, 
    232 A.3d 786
    , 798 (Pa.Super. 2020)
    (concluding that the hospital’s failure to establish that the members of the
    root cause analysis team were “professional healthcare providers” defeated a
    claim of PRPA privilege).
    However, Plaintiffs’ only argument against MCARE Act privilege is that,
    because it “was created first to aid the response” to the outbreak and then
    later submitted to the Committee, it was not “solely” created to satisfy MCARE
    Act obligations and, consequently, was not privileged. Id. at 31 (quoting not
    the evidence of record but COP’s appellate brief). We disagree.
    The lack of detail as to the timing of the report’s creation or the
    members of the root cause analysis team is immaterial to the applicability of
    the MCARE confidentiality provision.8 The evidence of record detailed above
    demonstrates that CHOP met its burden of establishing that the root cause
    ____________________________________________
    8  Of note, this Court was not presented with a claim of MCARE Act privilege
    in Ungurian v. Beyzman, 
    232 A.3d 786
    , 798 (Pa.Super. 2020).
    - 19 -
    J-A11003-22
    analysis report was (1) solely prepared for compliance with the MCARE Act
    duties for the Patient Safety Officer to report, and the Patient Safety
    Committee to receive, accounts of investigations into serious events and
    suggestions to improve patient safety; (2) arose out of matters that were
    indeed reviewed by the patient safety committee in accordance with § 310(b);
    and (3) was not otherwise available from original sources.       See 40 P.S.
    § 1303.311(a).     Therefore, pursuant to § 311(a), the root cause analysis
    document prepared for compliance with § 310(b) is itself subject to the
    privilege.   Thus, we reverse the portion of the trial court’s order directing
    CHOP to produce the root cause analysis report stamped Sanders CHOP PRIV
    000033-000039.
    B.     PowerPoint slides
    As detailed in our factual history above, Dr. Sammons prepared and
    presented PowerPoint slides on numerous occasions during and after the
    outbreak, namely: in “safety huddles” between August 24 and September 6,
    2016; at Infection Prevention & Control meetings on September 14 and
    October 12, 2016; at M&M conferences held with CHOP personnel on
    September 26, October 4, October 10, and October 11, 2016; and at the
    Scheie Eye Institute M&M conference on January 12, 2017.
    The trial court lumped all the PowerPoint presentations together and
    concluded that the materials “were not created for purposes of peer review
    triggering MCARE or PRPA protections.” Trial Court Opinion, 7/19/21, at 8.
    - 20 -
    J-A11003-22
    Rather, it determined that the documents were created in the course of
    addressing and stopping the outbreak and that they were only later sent to
    the peer review committee “in an effort to obtain privileged status.” Id. at 9.
    Further, the court determined that, by “announcing the investigations,
    findings, and remedial actions taken based upon the investigation” to the
    public in the article and abstract, CHOP waived the right to PRPA and MCARE
    protections concerning the investigation and remedial measures. Id. at 13.
    CHOP contends that different privileges applied to different PowerPoint
    presentations.     Specifically, it asserts that the presentations at the “safety
    huddles” are protected by MCARE; the presentation to the M&M conferences
    and at the Scheie Eye Institute were peer review meetings protected by the
    PRPA; and the presentations to the Infection Prevention & Control meetings
    are protected by both acts. See CHOP’s brief at 40. CHOP argues that the
    trial court’s focus on when the documents were created rather than the reason
    for it is unsupported in the law. Id. at 41.
    We first observe that the statutory privileges are not waived or
    otherwise invalidated by the fact that details of how the outbreak occurred
    and the measures that were ultimately implemented to reduce the risk of
    future outbreaks may have been disclosed in a published article and abstract.9
    ____________________________________________
    9  On appeal, Plaintiffs distance themselves from any claim that waiver was
    applicable, insisting that the trial court did not rule that any of the documents
    at issue were discoverable based upon waiver of a privilege, but instead
    (Footnote Continued Next Page)
    - 21 -
    J-A11003-22
    See Dodson, 
    supra at 1244
     (explaining that a privileged document does not
    become discoverable “simply because some of the information contained
    therein is available elsewhere”).
    Both the PRPA and the MCARE Act include varying protections for both
    documents and information, and provide, absolutely and without exception,
    that the protected materials shall not be discoverable or admissible, and that
    no one is permitted to testify in a civil action about protected information such
    as testimony before a committee or opinions formed as a result of committee
    meetings. See 63 P.S. § 425.4; 40 P.S. § 1303.311(a), (b). Both statutes,
    however, allow for the disclosure by committee members of information within
    their personal knowledge gleaned outside of their participation in the
    confidential proceedings.10 Id.
    Our prior discussion of the law indicates that both statutory privileges
    were designed to foster the frank and open discussion of the quality of health
    care services provided without fear that such will be used against the hospital
    or other professional health care providers in litigation. However, the disfavor
    ____________________________________________
    because CHOP “failed to substantiate that any of the materials at issue in this
    appeal met the qualifications for privilege.” Plaintiffs’ brief at 46.
    10 For example, as our summary at the outset of this opinion reveals, in her
    deposition Dr. Sammons provided Plaintiffs with factual information that was
    within her personal knowledge concerning the outbreak, the investigation, and
    CHOP’s response to it, rather than information she gleaned through protected
    materials or meetings. However, counsel did not permit Dr. Sammons to
    testify about information that she obtained from a peer review meeting. See
    Sammons Deposition, 10/6/20, at 323.
    - 22 -
    J-A11003-22
    with which evidentiary privileges are viewed remains. Thus, our legislature
    carefully chose language to establish that, while the facts and information
    independently brought into confidential meetings and investigations may be
    discoverable, the documents created for and proceedings themselves are what
    is privileged. As a court in one of our sister states aptly observed:
    Regardless of how information is used for improvement
    purposes or discussed by one party or entity outside of the
    process, the statute clearly does not intend that the peer review
    process should be voided, waived, or destroyed.           To hold
    otherwise subverts [the statute] and the purpose of the peer
    review process. One has only to read the statute to realize the
    . . . General Assembly did not create a privilege so frail and
    delicate as to be shattered by a mere reference to findings arising
    from the peer review process. If one cannot use the information
    generated from a peer review, the entire process is nullified and
    the statutory intent defeated.
    Stewart v. Vivian, M.D., 
    2012-Ohio-228
    , 
    2012 WL 195020
     at *8 (Ohio App.
    Jan. 23, 2012).
    Having rejected the notion of waiver, we consider whether the
    PowerPoint slides are materials protected by either statute, beginning with the
    “safety huddle” documents. CHOP maintains that the “safety huddles” were
    meetings of the patient safety committee in compliance with § 310(b) of
    MCARE, rendering slides created solely for presentation there to be privileged
    under § 311(a). Plaintiffs assert that the “slides were not formulated within a
    patient safety committee convened to evaluate the hospital’s response to a
    serious event,” but rather “as part of CHOP’s active response to an ongoing
    patient care emergency[.]” Plaintiff’s brief at 25-26.
    - 23 -
    J-A11003-22
    The affidavits of Drs. Boswinkel and Sammons indicate that the ad hoc
    meetings held in the NICU from the time the cluster of infections was reported
    until September 6, 2016, were in fulfillment of Dr. Boswinkel’s ongoing duty
    as Patient Safety Officer pursuant to § 309 to “[e]nsure the investigation of
    all reports of serious events and incidents,” to take any action “immediately
    necessary to ensure patient safety as a result of any investigation,” and to
    report actions taken as a result of an investigation to promote patient safety
    to the patient safety committee. 40 P.S. § 1303.309(2)-(4). See Boswinkel
    Affidavit, 2/19/21, at 2-3; Sammons Affidavit, 2/19/21, at 3-4.
    As such, these documents were not some form of incident reports or
    other mere business records designed to document the occurrences for future
    litigation or risk management. See Atkins v. Pottstown Mem’l Med. Ctr.,
    
    634 A.2d 258
    , 260 (Pa.Super. 1993) (holding incident report prepared for risk
    manager was an unprivileged business record because it was not part of an
    evaluation or review by a peer review committee); Venosh, supra at *11
    (holding event reports were not privileged where there was no evidence that
    they were generated to comply with an MCARE patient safety reporting
    requirement or ever reviewed by the patient safety committee). Rather, the
    evidence produced by CHOP established that the documents were (1) solely
    prepared for compliance with the MCARE Act duties for the Patient Safety
    Officer to conduct investigations into serious events and suggestions to
    improve patient safety; (2) arose out of matters that were indeed reviewed
    - 24 -
    J-A11003-22
    by the patient safety committee in accordance with § 310(b); and (3) were
    not otherwise available from original sources. See 40 P.S. § 1303.311(a).
    Accordingly, we reverse the trial court’s order to the extent that it compelled
    production of the slides stamped Sanders CHOP PRIV 000044-000107.
    For the same reasons, the PowerPoint slides prepared following the
    completion of the investigation for presentation at the formal Patient Safety
    Committee Meeting conducted on September 22, 2016, and the Safety M&M
    conference on September 26, 2016, are confidential materials pursuant to
    §§ 310(b) and 311 of the MCARE Act. See Boswinkel Affidavit, 2/19/21, at
    3-5. We therefore reverse the trial court’s order insofar as it requires CHOP
    to produce the documents stamped Sanders CHOP PRIV 000122-000159.
    Finally, we consider the PowerPoint slides prepared for the other M&M
    conferences held at CHOP and the Scheie Eye Institute Grand Rounds
    Conference.    As noted above, CHOP asserts that these are peer review
    materials that are protected by the PRPA. Plaintiffs contend that CHOP’s claim
    that these documents were privileged was properly rejected because, by not
    identifying each person who attended the M&M conferences, CHOP “failed to
    satisfy its burden to prove that the people who heard Dr. Sammons’[s]
    lectures were even capable of conducting peer review” or that the meetings
    were organized for evaluation “of the quality and efficiency of services ordered
    or performed by other professional health care providers.” Plaintiffs’ brief at
    42.
    - 25 -
    J-A11003-22
    We agree with CHOP that it produced evidence to show that these
    documents fell squarely within the protections of § 425.2 of the PRPA. As
    noted above, that section extends privilege to materials prepared for “(i)
    evaluating and improving the quality of health care rendered; (ii) reducing
    morbidity or mortality; or (iii) establishing and enforcing guidelines designed
    to keep within reasonable bounds the cost of health care.” 63 P.S. § 425.2.
    Contrary to Plaintiffs’ assertions, Dr. Sammons’s affidavit expressly indicates
    that each of the conferences was attended exclusively by professional health
    care providers and that the “slides were intended only for purposes of
    conducting peer review and improving the quality of health care.” Sammons
    Affidavit, 2/19/21, at 8-10, 12.
    Indeed, morbidity and mortality conferences attended solely by
    professional health care providers are precisely the peer review actions that
    the PRPA was designed to encourage.       As CHOP notes, one court recently
    observed that to find that M&M materials were not protected by the PHRA
    “would contravene the precise purpose for which [the PRPA’s] protections
    were enacted.” CHOP’s brief at 43 n.27 (quoting Morrissey v. Geisinger
    Cmty. Med. Ctr., 3:19-CV-894, 
    2020 WL 6877183
    , at *3 (M.D. Pa. Nov. 23,
    2020)). See also Bridenstine v. Saint Francis Hosp. & Med. Ctr., 
    68 A.3d 127
    , 133 (Conn. App. 2013) (affirming trial court ruling based upon its finding
    that the happenings at an M&M conference were subject to peer review
    privilege).   Therefore, we reverse the trial court’s direction for CHOP to
    - 26 -
    J-A11003-22
    produce the documents stamped Sanders CHOP PRIV 000129-000216 and
    000221-000245.
    C.     PowerPoint Slides and Minutes from IP&C Committee
    meetings on September 14 and October 12, 2016
    The trial court considered together Dr. Sammons’s PowerPoint slides
    presented at IP&C Committee meetings and the resultant meeting minutes.
    Although the IP&C Committee is a peer review committee, the trial court
    concluded that meetings were “held to address and stop the outbreak” and
    not for purposes of peer review committee. See Trial Court Opinion, 7/19/21,
    at 8. The court likened the documents to incident reports that were submitted
    to cloak them with privilege. 
    Id.
     Plaintiffs agree, and further argue that the
    documents were not solely prepared as part of the Patient Safety Committee’s
    evaluation of CHOP’s response to the outbreak, but rather “they were a part
    of the response itself.” Plaintiffs’ brief at 35.
    CHOP argues that the minutes from meetings of the IP&C Committee, a
    designated peer review committee, are protected by both the PRPA and
    MCARE. See CHOP’s brief at 40. It contends that the purpose of the meetings
    was to evaluate the ophthalmologists’ practice, the outbreak response, and
    compliance with CHOP procedures, as well as to discuss steps to improve
    healthcare quality and patient safety in the future. Id. at 15.
    Our review of the certified record reveals that CHOP produced evidence
    to support these contentions.        Specifically, the affidavit and deposition
    testimony of Dr. Sammons provides that the IP&C Committee is a peer review
    - 27 -
    J-A11003-22
    sub-committee of the Patient Safety Committee that conducts investigations
    and reports to the Patient Safety Committee. Dr. Sammons prepared slides
    to present at meetings to assist it in “evaluating the outbreak response by
    Infection   Prevention   providers   and      NICU   providers,   evaluated   the
    ophthalmologists’ practices, discussed monitoring of compliance with policies
    and procedures and evaluated next steps to prevent recurrence.” Sammons
    Affidavit, 2/19/21, at 6.   The Committee further discussed its upcoming
    reports to the Patient Safety Committee. Id.
    Again, § 310(b) of the MCARE Act tasks a patient safety committee with,
    inter alia, evaluating investigations directed by the patient safety officer,
    reviewing and evaluating the quality of the hospital’s patient safety measures,
    and making recommendations to eliminate future serious events. See 40 P.S.
    § 1303.310(b)(2)-(4). That is precisely what Dr. Sammons described. The
    notion proffered by Plaintiffs and accepted by the trial court that a patient
    safety committee must merely accept incident reports and not perform a
    review and evaluation or recommend changes in procedures until after
    a serious event has completely run its course is irrational and unsupported by
    the language of the MCARE Act. On the contrary, such is the exact type of
    frank, open, and proactive proceedings that the Act sought to implement in
    furtherance of its goal “to reduce and eliminate medical errors by identifying
    problems and implementing solutions that promote patient safety.” 40 P.S.
    § 1303.102(5). Therefore, without having to consider the PRPA, it is clear to
    - 28 -
    J-A11003-22
    us that the slides Dr. Sammons presented at the IP&C Committee meetings
    and the minutes taken of those meetings are privileged by § 311(a).
    Consequently, we reverse the trial court's order to the extent that it mandated
    production of the documents stamped Sanders CHOP PRIV 000006-000032,
    000108-000122, and 000217-220.
    D.    PowerPoint slides from the Patient Safety Committee
    meeting on September 22, 2016
    The next document at issue involves the slides Dr. Sammons presented
    at the Patient Safety Committee meeting that the IP&C Committee discussed
    in the documents we just reviewed. CHOP again asserts MCARE Act privilege,
    and Plaintiffs again contend that the slides were part of the response rather
    than a review of the hospital’s response. See Plaintiff’s brief at 37. For the
    reasons offered above, we conclude that CHOP established that the documents
    were utilized in the report to the Patient Safety Committee in accordance with
    § 310(d) of the MCARE Act and are consequently protected by § 311(a).
    Hence, we reverse the trial court’s order to the extent that it mandated
    production of the documents stamped Sanders CHOP PRIV 000122-000128.
    E.    Intranet postings to CHOP personnel about the outbreak
    The next documents at issue identified in CHOP’s privilege log were two
    postings on CHOP’s intranet website:     one in August 2016 entitled “CHOP
    Serious Safety Events” and one in February 2017 entitled “Learning from our
    Safety Events.”   The trial court ruled that no privilege applied to these
    materials, which were available to all CHOP personnel who had access to a
    - 29 -
    J-A11003-22
    computer.     In doing so, the court did not offer a detailed analysis of the
    document which it described as a “job ad.” See Trial Court Opinion, 7/19/21,
    at 8.
    CHOP argues that these intranet posts fell within the MCARE privilege
    because they “notified CHOP personnel of events for the purpose of
    compliance with (d) of the section 310(b) or of reporting under section 309(4),
    and arise out of matters reviewed by the patient safety committee pursuant
    to section 310(b) or the governing board of a medical facility pursuant to
    section 310(b).” CHOP’s brief at 18.
    We disagree. Dr. Boswinkel’s affidavit indicates that the purpose of the
    posts “was to notify CHOP personnel of events to increase awareness,
    encourage learning from events, and to recommend actions to prevent future
    serious events or incidents.” Boswinkel Affidavit, 2/19/21, at 7. Further, the
    communications “accomplish the general purposes of promoting patient
    safety, quality improvement, and improving patient care.” Id.
    The MCARE Act does not protect any and all materials involving patient
    safety. Rather, it addresses in §§ 309 and 310(d) reports to the patient safety
    committee and the committee’s internal deliberations about what occurred
    and what altered policies might better serve patient safety. CHOP points to
    nothing within the MCARE Act that protects subsequent communications from
    the patient safety committee to the institution at large announcing the new
    policies decided upon as a result of their confidential proceedings. We discern
    - 30 -
    J-A11003-22
    no provision of the Act that expresses an intention to forever shield from
    discovery hospital policies that arose from patient safety committee meetings.
    Rather, it seeks to protect the confidentiality of the investigation and
    assessment of the serious events that occasioned the policies.
    Therefore, CHOP has failed to establish that the trial court committed
    an error of law in ordering the production of the intranet posts stamped
    Sanders CHOP PRIV 000040-000043.
    F.     Redacted ophthalmology emails
    Finally, CHOP argues that the trial court erred in ordering the full
    disclosure of what it describes as “redacted ophthalmology emails (CHOP PRIV
    280-285).” CHOP’s brief at 45. It maintains that “[t]he redacted portion of
    the emails contained information that is protected from disclosure pursuant to
    the MCARE and peer review privileges because it references action plans that
    were part of the peer review process and taken under MCARE precautions.”
    Id. at 45-46.
    That is the extent of CHOP’s argument. It offers no indication that it
    provided the trial court with evidence that these emails were made pursuant
    to a peer review evaluation or in furtherance of MCARE reporting. Instead,
    CHOP appears to assert, as it did with the intranet postings, that the emails
    contain information about the new policy or procedures that resulted from the
    earlier peer review or patient safety proceedings. As such, CHOP failed to
    meet    its   burden   of   establishing   that   these   emails   were   privileged
    - 31 -
    J-A11003-22
    communications within CHOP’s peer review or patient safety apparatus.
    Hence, we have no cause to disturb the trial court’s ruling as to these
    documents.
    IV.   Conclusion
    We understand that Plaintiffs have the ultimate burden of proving that
    their heartbreaking losses resulted from CHOP’s negligence, and that
    accessing the documents at issue would lighten that burden. However, our
    legislature has recognized that the public has a competing, compelling interest
    in creating an environment in which improving the quality of health care by
    examining and learning from past incidents is not eschewed for fear that the
    honest assessment thereof could be used against health care providers to
    impose legal liability. In this vein, we find our Supreme Court’s observations
    on the effects of peer review privilege are applicable to both of the
    confidentiality provisions at issue in this appeal:
    We recognize that the statutory privilege as thus understood may
    prevent civil plaintiffs from obtaining some documents tending to
    show that their injuries were caused by the defendant’s
    negligence, whether it be that of the physician or the facility at
    which he or she maintains privileges. However, the legislative
    body is presumed to have balanced that consideration against
    others, discussed above, which may be in tension with it, and to
    have intentionally used language applying to a variety of
    committees whose proceedings and records involve peer review
    [and MCARE Act patient safety reporting]. . . .
    [T]he convergence of medicine and litigation at times brings about
    discordant results:     the furtherance of one end may
    commensurately disadvantage the other.              All privileges
    necessarily hinder to some degree the information available to
    opposing litigants. Similarly, assigning paramount status to a
    - 32 -
    J-A11003-22
    plaintiff’s pursuit of a legal remedy can strike a fatal blow to a
    procedural framework erected to enhance patient safety. The
    General Assembly, in enacting [the statutory privileges], clearly
    voiced an intention to allow for the confidentiality necessary for
    meaningful peer [and MCARE Act] review.
    Leadbitter supra at 1177–78 (cleaned up).
    We have made our rulings herein to fulfill our duty to ensure the faithful
    application of the policy determinations and interest-balancing enacted by the
    Commonwealth’s elected representatives.
    Orders affirmed in part and reversed in part. Case remanded for further
    proceedings consistent with this opinion. Jurisdiction relinquished.
    Judge Stabile joins this Opinion.
    Judge McLaughlin files a Concurring & Dissenting Opinion.
    Judgment Entered.
    Joseph D. Seletyn, Esq.
    Prothonotary
    Date: 11/22/2022
    - 33 -
    

Document Info

Docket Number: 646 EDA 2021

Judges: Bowes, J.

Filed Date: 11/22/2022

Precedential Status: Precedential

Modified Date: 11/22/2022